APOA5 Antikörper (AA 20-363)
Kurzübersicht für APOA5 Antikörper (AA 20-363) (ABIN1842850)
Target
Alle APOA5 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 20-363
-
Aufreinigung
- Purified antibody
-
Immunogen
- Purified recombinant fragment of human APOA5 (AA: 20-363) expressed in E. Coli.
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.03 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
-
-
- APOA5 (Apolipoprotein A-V (APOA5))
-
Andere Bezeichnung
- Apoa5
-
Hintergrund
- Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
-
Molekulargewicht
- 41 kDa
-
Gen-ID
- 116519
-
UniProt
- Q6Q788
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism
Target
-